VLA-4 inhibitor compounds
US6756378B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 28, 2001 |
| Grant date | Jun 29, 2004 |
| Priority date | — |
| Expiry date | Dec 28, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.